An inexpensive investigational vaccine known as AKS-452 is stable for weeks at room temperature and can potentially be used for both prime and boost vaccination.
The vaccine developer, Akston Biosciences (Beverly, Mass.), has hooked up with LakePharma, a San Carlos, Calif.-based contract research, development and manufacturing outsourcing organization, to manufacture the vaccine. Phase 1/2 clinical trials for the vaccine will begin later this month at the University Medical Center Groningen in the Netherlands.
The vaccine candidate, pictured on the left, has shown promise in preclinical animal studies where it is initiated robust antibody production at microgram doses.
The AKS-452 can be produced using conventional antibody manufacturing techniques.
The developer describes the vaccine as “the most advanced” investigational COVID-19-specific Fc fusion protein vaccine.
Filed Under: clinical trials, Drug Discovery, Infectious Disease